Lymph Node Metastases Detection Using Gd<sub>2</sub>O<sub>3</sub>@PCD as Novel Multifunctional Contrast Imaging Agent in Metabolic Magnetic Resonance Molecular Imaging

<div>(a, b, c) Schematic representation of the synthesis of the passive targeted Gd-based Nano-CA and Lymph node detection by using an MRI contrast agent that binds to PCDs. Metabolically nanoparticles with a size between 20 and 40 nm have a rapid uptake into metastatic axillary lymph nodes as well as an extremely long retention time.</div>

Contrast Media & Molecular Imaging

fig1

Figure 1

Figure 1: Lymph Node Metastases Detection Using Gd<sub>2</sub>O<sub>3</sub>@PCD as Novel Multifunctional Contrast Imaging Agent in Metabolic Magnetic Resonance Molecular Imaging 

Figure 1 | Lymph Node Metastases Detection Using Gd2O3@PCD as Novel Multifunctional Contrast Imaging Agent in Metabolic Magnetic Resonance Molecular Imaging 